BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT05491642
- Locations
- π§π¬
Medical Center Comac Medical EOOD, Sofia, Bulgaria
π©πͺCharitΓ© Research Organisation GmbH, Berlin, Germany
π©πͺCTC North GmbH & Co. KG, Hamburg, Germany
A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 541
- Registration Number
- NCT05485805
- Locations
- πΊπΈ
JBR Clinical Research, Salt Lake City, Utah, United States
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT05481528
- Locations
- π©πͺ
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT05477953
- Locations
- ππ³
Many locations, Multiple Locations, Honduras
πΊπΎMany Locations, Multiple Locations, Uruguay
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3
- Registration Number
- NCT05473715
- Locations
- π¬π§
Bristol Eye Hospital, Bristol, United Kingdom
π¨π¦GOGiunta ophtalmologie, Sherbrooke, Quebec, Canada
π¨π¦Retina Center of Ottawa, Ottawa, Ontario, Canada
A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT05471817
- Locations
- π©πͺ
CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT05471830
- Locations
- πΊπΈ
Bayer, Whippany, New Jersey, United States
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2437
- Registration Number
- NCT05461807
- Locations
- π©πͺ
Bayer, Wuppertal, Germany
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT05457283
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
πΊπΈPhoenix Children's Hospital | Main - Transplant Department, Phoenix, Arizona, United States
πΊπΈUniversity of California San Diego (UCSD), La Jolla, California, United States
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 152233
- Registration Number
- NCT05428397
- Locations
- π©πͺ
Bayer, Wuppertal, Germany
Β© Copyright 2024. All Rights Reserved by MedPath